Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 3018-3021

  Clavel, Cyril ^a   Peytavin, Gilles ^b   Tubiana, Roland ^a   Soulié, Cathia ^a   Crenn Hebert, Catherine ^c   Heard, Isabelle ^a   Bissuel, François ^d   Ichou, Houria ^c   Ferreira, Claudia ^c   Katlama, Christine ^a   Marcelin, Anne Geneviève ^a   Mandelbrot, Laurent ^c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d Department of Infectious Diseases   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; OMEPRAZOLE; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CERVICOVAGINAL FLUID; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT DURATION; VAGINA DISCHARGE; VAGINITIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CERVIX UTERI; FEMALE; HIV-1; HUMANS; MIDDLE AGED; PYRROLIDINONES; VAGINA;

EID: 79956314183     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01460-10     Document Type: Article

References (18)

1. Barau, C., et al. 2010. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob. Agents Chemother. 54:937-939.
2. Cianfriglia, M., et al. 2007. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 4:17.
3. Cu-Uvin, S., et al. 2000. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 14:415-421. (Pubitemid 30182438)
4. De Pasquale, M. P., et al. 2003. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 34:37-44.
5. Dumond, J. B., et al. 2009. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:546-553.
6. Dumond, J. B., et al. 2007. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21:1899-1907. (Pubitemid 47329766)
7. Ghosn, J., et al. 2008. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J. Antimicrob. Chemother. 61:1344-1347.
8. Iwamoto, M., et al. 2009. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48:489-492.
9. Iwamoto, M., et al. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83:293-299.
10. Jones, A. E., et al. 2009. First-dose and steady-state pharmacokinetics of raltegravir in the genital tract of HIV negative women, abstr. 0-06. 10th Int. Workshop Clin. Pharmacol. HIV Ther., Amsterdam, Netherlands, 15 to 17 April 2009.
11. Jung, B. H., N. L. Rezk, A. S. Bridges, A. H. Corbett, and A. D. Kashuba. 2007. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 21:1095-1104.
12. Kemal, K. S., et al. 2007. HIV-1 drug resistance in variants from the female genital tract and plasma. J. Infect. Dis. 195:535-545.
13. Kwara, A., et al. 2008. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis. 46:719-725.
14. Lambert-Niclot, S., et al. 2010. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob. Agents Chemother. 54:4910-4913.
15. Markowitz, M., et al. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
16. Pasquier, C., et al. 2009. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J. Clin. Microbiol. 47:2883-2887.
17. Roquebert, B., et al. 2008. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemother. 62:914-920.
18. Si-Mohamed, A., et al. 2000. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J. Infect. Dis. 182:112-122.